Stock News: What You Need to Know

Aster DM Healthcare is investing Rs 1,000 crore to enhance bed capacity over the next three years. This will definitely help improve healthcare facilities and access for people in need.

It's impressive to see Aster DM Healthcare's plans to expand its operations in India by investing around Rs 1,000 crore from the proceeds of its GCC business divestment. The company aspires to add 1,700 beds by 2026-27 and scale up its labs and pharmacy business to emerge as one of the leading integrated healthcare providers in India. Additionally, the company's Board has approved a special dividend of Rs 118 per share for its shareholders, which will be paid by April 23, 2024. Aster DM Healthcare's shares surged over 14% on Monday to hit a fresh 52-week high on BSE, despite the broader market's weak trend. Despite the dividend payout, the company will still retain Rs 1,500 crore from the sale of its GCC business.

Follow our blog for all the market action

Jefferies has decided to retain its 'buy' rating on HDFC Bank and has predicted a significant upsurge of over 20%.

It seems like Jefferies, a global brokerage firm, has maintained a 'buy' rating on HDFC Bank, India's biggest private lender. According to Jefferies analysts, an improvement in HDFC Bank's net interest margins (NIMs) is crucial to boosting the return on asset (RoA) and re-rating valuations. They have assigned a target price of Rs 1,800 per share, indicating a 20 percent upside from current levels.

While HDFC Bank's stock has declined over 12 percent this year, it has outperformed the benchmark Nifty, which has risen by 2.4 percent. Jefferies analysts believe that HDFC Bank's potential for credit growth over the next five years is significant, and deposit market share gains could drive loan growth of 13 percent if deposits grow at a compounded annual growth rate (CAGR) of 17-18 percent.

Marksans Pharma has seen an impressive rally of over 100% in the past 12 months.

It seems that the Massachusetts Institute of Technology has recently acquired a 1.45% stake or 66 lakh shares in Marksans Pharma through a block deal at ₹158 apiece. This is based on the latest data available on the exchanges, as MIT did not own any stake in the company during the previous quarter.

Marksans Pharma has a number of other major public shareholders, including OrbiMed Asia IV Mauritius FVCI Ltd., which currently holds a 10.88% stake in the company. The promoters of Marksans Pharma still hold a majority stake of 43.85%. The company's shares have been performing well, having risen over 100% in the past year.Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint.

We advise investors to check with certified experts before making any investment decisions.